Rimonabant News
Tacconi moves back to Merck to head investigational obesity drug
Merck has brought back consumer marketing guru Len Tacconi to serve as global brand leader for its lead investigational component for obesity, taranabant.
Tacconi, who first joined Merck in 1996 to build its consumer...
Weight loss pill warning issued
A weight-loss drug used by thousands is unsafe for those also taking antidepressants, health watchdogs warn.
The European Medicines Agency advises patients with ongoing major depression or those on antidepressants against...
Diet Drug Acomplia (Rimonabant) Doubles Risk of Depression -- European Regulators
Taking diet drug Acomplia (rimonabant) approximately doubles your risk of depression, and the risk may be even higher if you have a past history of depression, according to the European Medicines Agency (EMEA).
"This doubling of...
UK Regulator: 1 Person in 10 on Acomplia Experiences Psychiatric Side Effects
Approximately one person in 10 taking diet drug Acomplia (rimonabant) experiences psychiatric side effects and about one person in 100 experiences suicidal thoughts, according to U.K. regulators.
Of some 41,000 patients treated...
Diet Drug Acomplia to Remain on Sale in Europe With Stronger Warning
Diet drug Acomplia (rimonabant) will remain on the market in Europe but will carry a stronger safety warning about psychiatric side-effects, European regulators decided on July 19th.
The European Medicines Agency (EMEA) made the...